参考文献/References:
[1]张红彩,李峥.精神分裂症患者家庭负担的研究进展[J].中华护理杂志,2009,44(8):758-761. [2]冉柳毅,姜红燕,许秀峰.精神分裂症患者细胞因子研究新进展[J].精神医学杂志,2015(2):156-158. [3]Baxter AJ,Charlson FJ,Somerville AJ,et al.Mental disorders as risk factors:assessing the evidence for the Global Burden of Disease Study[J].Bmc Medicine,2011,9(1):134. [4]Hennekens CH.Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia[J].Journal of Clinical Psychiatry,2007,68(4):4-7. [5]Os JV,Kapur S.Schizophrenia.Lancet[J].Lancet,2009,374(9690):635-645. [6]Davis D,Harrell S.Strategies Used by Chinese Families Coping with Schizophrenia[M].Chinese Families in the Post-Mao Era,1993:277-306. [7]Donnelly JE,Ptomey LT,Goetz JR,et al.Weight management for adolescents with intellectual and developmental disabilities:Rationale and design for an 18 month randomized trial[J]. Contemporary Clinical Trials,2013,36(1):116-124. [8]Mugwanya KK,Donnell D,Celum C,et al.Sexual Behaviour of Heterosexual Men and Women Receiving Antiretroviral Pre-Exposure Prophylaxis For HIV Prevention:Post-Unblinding Analysis of the Partners PrEP Study[J].Lancet Infectious Diseases,2013,13(12):1021-1028. [9]Wall KM,William K,Bellington V,et al.Hormonal Contraceptive Use Among HIV-Positive Women and HIV Transmission Risk to Male Partners,Zambia,1994-2012[J].Journal of Infectious Diseases, 2016,214(7):1063-1071. [10]Karlawish J,Cary MS,Rubright J,et al.How redesigning AD clinical trials might increase study partners’willingness to participate[J].Neurology,2008,71(23):1883. [11]Grill JD,Monsell S,Karlawish J.Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer’s Disease Clinical Trials[J].Dementia&Geriatric Cognitive Disorders,2012,33(5):334-340. [12]Chan SW.Global perspective of burden of family caregivers for persons with schizophrenia[J].Archives of Psychiatric Nursing,2011,25(5):339-349. [13]张强,蒙萍,单爱莲.关于药物临床试验方案中纳入、排除标准的若干思考[J].中国临床药理学杂志,2017,33(2):99-101. [14]郭春雪,胡良平.正确把握精神卫生临床试验设计三要素的要领(Ⅰ)-受试对象[J].四川精神卫生,2016,29(3):197-201. [15]王书新,郭月芹,张淑君,等.受试者相关因素对临床试验完成效果的影响分析[J].中国药业,2009,18(3):34-35. [16]张营,石磊,江伟健,等,临床试验中依从性的影响因素及其对策[J].中国药业,2012,21(2):13-14. [17]王霞,徐蓉,杨敏.精神分裂症患者主要照顾者负担的研究进展[J].护理学杂志,2015,30(7):95-99. [18]谭剑,余晓琼,韩志琴,等.农村精神分裂症自然病程流行病学调查[J].临床心身疾病杂志,2009,15(2):156-157.
相似文献/References:
[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Medical Information,2018,31(19):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Medical Information,2018,31(19):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症
疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Medical Information,2018,31(19):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状
疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,31(19):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Medical Information,2022,35(19):137.[doi:10.3969/j.issn.1006-1959.2022.10.033]
[6]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Medical Information,2018,31(19):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[7]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
WU Jin-li.Clinical Application of Aripiprazole[J].Medical Information,2018,31(19):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[8]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Medical Information,2018,31(19):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Medical Information,2018,31(19):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Medical Information,2019,32(19):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]